Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.7600
+0.0048 (0.64%)
At close: Aug 15, 2025, 4:00 PM
0.7444
-0.0156 (-2.05%)
After-hours: Aug 15, 2025, 7:59 PM EDT
Longeveron Revenue
Longeveron had revenue of $316.00K in the quarter ending June 30, 2025, a decrease of -32.48%. This brings the company's revenue in the last twelve months to $2.07M, up 68.67% year-over-year. In the year 2024, Longeveron had annual revenue of $2.39M with 237.38% growth.
Revenue (ttm)
$2.07M
Revenue Growth
+68.67%
P/S Ratio
5.37
Revenue / Employee
$82,920
Employees
25
Market Cap
15.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
LGVN News
- 2 days ago - Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 days ago - Longeveron Announces Closing Of Up To $17.5 Million Public Offering - GlobeNewsWire
- 7 days ago - Longeveron Announces Up To $17.5 Million Public Offering - GlobeNewsWire
- 10 days ago - Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - GlobeNewsWire
- 25 days ago - Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - GlobeNewsWire
- 5 weeks ago - Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - GlobeNewsWire
- 7 weeks ago - Longeveron® Appoints Than Powell as Chief Business Officer - GlobeNewsWire